Pancreas divisum—failure of fusion of the dorsal and ventral pancreatic ducts—is relatively well known as the most common congenital anomaly of the pancreatic duct, of with an incidence approximately 10% of all embryos. And there is a rare anomaly similar to pancreas divisum in which doubled ducts are formed. This condition is a rare developmental anomaly called pancreas bifidum or bifid pancreas or fish tail pancreas. This report describes a patient with pancreas bifidum who had 2 separated ducts within the pancreas from tail to neck but did not have a separated parenchyma. We hope that this report helps pancreatic surgeons to have knowledge of pancreas bifidum and helps them to be prepared for this anatomical variant.
Embryonic Structures ; Hope ; Humans ; Incidence ; Neck ; Pancreas ; Pancreatic Ducts ; Surgeons ; Tail

PURPOSE: The aim of this study is to elucidate the fundamental characteristics of the laparoscopic splenectomy and to compare the clinical outcomes and postoperative pain between the laparoscopic splenectomy and the conventional open splenectomy. METHODS: From January 2005 to January 2013, 28 patients underwent a splenectomy at Pusan National University Hospital, South Korea (PNUH). This study was a comparison of the demographic features and clinical results between the laparoscopic splenectomy (n=15) and open splenectomy (n=13). RESULTS: For the two groups of patients, the following were similar: estimated blood loss, transfusion, operative time, duration of patient-controlled analgesia, and the additional administration of painkillers. In the laparoscopic splenectomy group, the postoperative hospital stay (7.9+/-1.6 days versus 5.9+/-1.4 days, p=0.002) and the diet start time (2.7+/-0.3 days versus 1.8+/-0.8 days, p=0.003) were significantly shorter. No significant difference in postoperative pain was observed between the two groups. CONCLUSION: In this study, there was no benefit for postoperative pain in the LS group. However, the laparoscopic splenectomy has several benefits, including a shorter postoperative hospital stay and an earlier diet start time; in addition, it is feasible and safe.
Analgesia, Patient-Controlled ; Busan ; Diet ; Humans ; Korea ; Length of Stay ; Operative Time ; Pain, Postoperative* ; Splenectomy*

The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.

The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.

The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.

Recently the use of I-PSS (International prostate symptom score) is highly recommended for the evaluation of symptomatic benign prostatic hyperplasia (BPH) and many linguistic translations have been made. Regardless the validity and reliability of linguistic translation, there might be several social and cultural factors which affect to the symptom severity in BPH. We tried to show the prevalence of prostatism and the effect of social and cultural background which could affect to the results I-PSS questionnaire in Korea. A total of 841 men (40~79 years) who visited 4 health care center were included. Because of 107 men had medico-surgical history relating to voiding, final eligible subjects were 734. Total symptom scores increased by age decades (40~49, 50~59, 60~ 69, 70~79; median 7, 8, 11, 12 respectively). The rate of mild (0~7); moderate (8~19); and severe (20~35) symptom in 40th, 50th, 60th and 70th were 55.5%; 39.3%; 1.2%, 45.4%; 46.5%; 8.1%, 30.4%; 53.9%; 15.7% and 28.1%; 43.8%; 28.1% respectively. One cause of these high prevalence of prostatism in Korea is relatively very small proportion of readily treated BPH patients in general population (0.5%). Another factor of the high prevalence of prostatism is thought to be the different social and cultural concept to voiding status. These factors limit comparability of I-PSS questionnaire between different countries.
Delivery of Health Care ; Humans ; Korea* ; Linguistics ; Male ; Prevalence* ; Prostate ; Prostatic Hyperplasia ; Prostatism* ; Surveys and Questionnaires ; Reproducibility of Results ; Translations

Recently developed International Prostate Symptom Score(I-PSS) is highly recommended for the evaluation of urinary symptoms in benign prostatic hyperplasia(BPH) and many linguistic translations have been made. English version of I-PSS was translated into Korean. Three groups of urologists and ordinary people participated for the translation and back-translation of I-PSS. A Korean version was finalized and translation validity was assessed by a survey with 48 English speaking Korean aged men. Test-retest reliability was confirmed by an another questionnaire survey with 76 aged men. Translation of I-PSS into Korean was valid. The I-PSS Korean version was internally consistent and sensitive as well as specific for the discrimination of symptomatic groups. Also test-retest reliability was acceptable.
Discrimination (Psychology) ; Humans ; Linguistics ; Male ; Prostate ; Surveys and Questionnaires ; Reproducibility of Results* ; Translations

Prostate-specific antigen(PSA) in serum exists in several molecular forms that can be measured by immunodetectable assays; free PSA, PSA complexed to alpha1-antichymotripsin and total PSA, which represents the sum of the free and complexed forms. We have determined the amount and ratio of these forms may be seful for increasing the ability of PSA to be used in distinguishing prostate cancer(PCa) from benign prostatic hyperplasia(BPH). We evaluated 117 asymptomatic healthy male controls(mean age 55.8, range 50-71) with no clinical evidence of PCa, 125 men with symptomatic BPH(mean age 67.6, range 52-89) who underwent prostatic surgery(open prostatectomy or TLRP) and 14 men with biopsy-proven, untreated PCa(mean age 71.3 range 54-86). Using ACS-PSA2 assay(Ciba-Corning). we measured the free PSA(F), total PSA(T) and free/total(F/T) ratio. The method utilized was monoclonal-polyclonal immunometric, chemiluminescent assay, using a standardized calibrator 90:10. We also performed total PSA measurement with Tandem-R PSA assay(Hybritech). Correlation between ACS-PSA2 assay and Tandem-RPSA assay was excellent (r2=0.93). Receivr operating characteristics(ROC) analyses between them showed very similar performances. ROC analysis of free to total PSA ratio was more superior than that of free form PSA only. When all subjects were included, the ratio of free to total PSA in controls, BPH and PCa were 0.27, 0.24 and 0.07, respectively. which significantly differentiated between PCa and benign conditions(p<0.01). When the cut-off value (Fr) was set into 0.12, its diagnostic sensitivity and specificity were 86% and 84%, respectively. These findings suggest that free to total PSA ratio may enhance the ability to distinguish benign histologic conditions from cancer.
Humans ; Luminescent Measurements ; Male ; Passive Cutaneous Anaphylaxis ; Prostate ; Prostate-Specific Antigen* ; Prostatectomy ; ROC Curve ; Sensitivity and Specificity